Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBX-303061 in Relapsed/Refractory B-Cell Malignancies
NCT06590961Phase 1Recruiting
- Sponsor
- Ubix Therapeutics
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of UBX-303061 in B-cell malignancy, sponsored by Ubix Therapeutics. Primary endpoints: Number of subjects with Protocol Specified Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose and/or Recommended Phase 1b Dose at 9 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
UBX-303061
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT06590961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590961.